The following communication was sent to certain holders of its ordinary shares by Teva Pharmaceutical Industries Limited:
| | |
| | TEVA PHARMACEUTICAL INDUSTRIES LIMITED 2021 ANNUAL MEETING OF SHAREHOLDERS June 14, 2021 4:00 p.m. (Israel time), 9:00 a.m. (Eastern time) Virtual format only Participation instructions for the Teva Pharmaceutical Industries Limited 2021 Annual Meeting of Shareholders and information on how to vote through the online meeting platform are available in the proxy statement which can be viewed at www.tevapharm.com/2021proxymaterials. |
Important Notice Regarding the Availability of Proxy Materials for the
Shareholder Meeting to be Held on June 14, 2021.
Notice is hereby given that the 2021 Annual Meeting of Shareholders (the “meeting”) of Teva Pharmaceutical Industries Limited (“Teva”) will be held in a virtual format on June 14, 2021 at 4:00 p.m. (Israel time), 9:00 a.m. (Eastern time).
This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. This is not a form for voting.
The Notice of Annual Meeting of Shareholders and Proxy Statement and Annual Report are available at www.tevapharm.com/2021proxymaterials.
If you want to receive a paper copy or an e-mail with links to the electronic materials, you must request one. There is no charge to you for requesting a copy. Please make your request for a copy as instructed below on or before May 27, 2021 to facilitate timely delivery. Unless requested, you will not otherwise receive a paper or email copy.
Matters intended to be acted upon at the meeting are listed below.
1. | To appoint the following persons: Rosemary A. Crane, Abbas Hussain, Gerald M. Lieberman and Prof. Ronit Satchi-Fainaro to serve on the Board of Directors until our 2024 annual meeting of shareholders. |
2. | To approve, on a non-binding advisory basis, the compensation for Teva’s named executive officers. |
3. | To appoint Kesselman & Kesselman, a member of PricewaterhouseCoopers International Ltd., as Teva’s independent registered public accounting firm until Teva’s 2022 annual meeting of shareholders. |
In addition, shareholders will consider Teva’s annual consolidated financial statements for the year ended December 31, 2020.
The Board of Directors recommends that you vote FOR all proposals.